Issue 40, 2024

In vivo safety evaluation and tracing of arginylglycylaspartic acid-engineered phage nanofiber in murine model

Abstract

The engineered phage YSY184, mimicking the extracellular matrix nanofiber, effectively promotes stem cell differentiation and angiogenesis. This study evaluated its safety in a mouse model, monitoring weight, immunogenicity, spleen immune responses, and macrophage infiltration. Rapid clearance of YSY184 was observed, with peak tissue presence within three hours, significantly reduced by 24 hours, and negligible after one month. No adverse physiological or pathological effects were detected post-administration, affirming YSY184's safety and underscore its potential for therapeutic use, warranting further clinical exploration.

Graphical abstract: In vivo safety evaluation and tracing of arginylglycylaspartic acid-engineered phage nanofiber in murine model

Supplementary files

Article information

Article type
Paper
Submitted
15 Apr. 2024
Accepted
14 Sept. 2024
First published
16 Sept. 2024

J. Mater. Chem. B, 2024,12, 10258-10271

In vivo safety evaluation and tracing of arginylglycylaspartic acid-engineered phage nanofiber in murine model

K. R. Shrestha, S. Kim, A. Jo, M. Ragothaman and S. Y. Yoo, J. Mater. Chem. B, 2024, 12, 10258 DOI: 10.1039/D4TB00823E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements